Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abemaciclib + bicalutamide in AR+ triple-negative breast cancer
2022-502272-23-00Phase 2Authorised
- Sponsor
- UZ Leuven
- Start
- Nov 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of abemaciclib and bicalutamide in triple-negative breast cancer (TNBC) and breast cancer (4 cohorts), sponsored by UZ Leuven. Primary endpoint: Disease control rate (DCR) at 16 weeks (all cohorts combined). Planned start Nov 2023; status: authorised.
02
Drugs
abemaciclibbicalutamide
03
Conditions
triple-negative breast cancer (TNBC)breast cancer
Beyond the preview
Go deeper on 2022-502272-23-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502272-23-00.